Incidence and Clinical Features of PHACE Syndrome
Incidence, Risk Factor and Clinical Features of PHACE Syndrome
This study will include infants seen at three hospitals who have a segmental infantile hemangioma, a blood vessel growth affecting a broad area of skin. Eligible areas include the scalp, face, neck, upper chest or back, and shoulder or upper arm. The study will measure how often PHACE syndrome is found in infants with enough clinical information to determine the diagnosis. PHACE syndrome can involve differences in the development of the brain, arteries, heart, eyes, or the midline of the chest and abdomen. The study team will describe these findings and the hemangiomas. The treating clinicians will manage evaluation and care.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Descrizione dettagliata
This prospective observational cohort will consecutively invite infants with a clinician-confirmed segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity at their first qualifying presentation to a participating center. Infants can enroll regardless of whether a PHACE evaluation or diagnosis is already documented. Prior evaluation and referral source will be recorded. Each infant will be enrolled once. A parent or legal guardian will provide written informed consent.
At enrollment, study clinicians will record age, sex, the anatomic distribution and laterality of the segmental lesions, the longest diameter of the largest qualifying lesion, and lesion depth. Photographs will be recorded when permitted by the protocol and consent. Each infant will be assigned to one anatomic stratum. The strata are head involvement with or without other sites, isolated neck, isolated upper trunk, isolated proximal upper extremity, and multiple sites without head involvement. All involved regions will also be recorded.
The study will collect clinical findings and results of clinically indicated assessments, including examination for ocular and ventral midline abnormalities, echocardiography, and magnetic resonance imaging and angiography of the head and neck, with aortic arch assessment. The treating team will determine which examinations and treatments are clinically appropriate. Prior assessments can contribute to classification when they meet the same protocol criteria for adequacy.
A central panel will apply the revised 2016 PHACE consensus diagnostic criteria. A hemangioma of the head, including the scalp, that exceeds 5 cm in diameter supports a diagnosis of definite PHACE when accompanied by at least one major or two minor criteria. For large segmental hemangiomas of the neck, upper trunk, or trunk with proximal upper-extremity involvement, definite PHACE requires at least two major criteria. Isolated proximal upper-extremity lesions will be described separately. Classification as definite PHACE will require documented fulfillment of the consensus criteria.
The primary analysis will include infants with a protocol-defined evaluable assessment by six months after enrollment. An evaluable assessment requires interpretable documentation of the prespecified core clinical, cardiac, and neurovascular evaluations, irrespective of the diagnostic classification. Definite PHACE, possible PHACE, and neither category will be reported separately. Inadequate evaluations will be recorded with the reason and retained in the enrollment count. The study will report the assessment completion proportion and the definite PHACE proportion with 95% confidence intervals overall and by anatomic stratum where estimable.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Yi Ji Ji, PhD
- Numero di telefono: 02885423453
- Email: jijiyuanyuan@163.com
Luoghi di studio
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 610041
- Reclutamento
- Children's Hospital of Fudan University
-
Contatto:
- Zuopeng Wang Wang, PhD
- Numero di telefono: 028854223
- Email: 1192207223@qq.com
-
-
Sichuan
-
Chengdu, Sichuan, Cina
- Reclutamento
- West China Hospital of Sichuan University
-
Contatto:
- Yi Ji Ji, PhD
- Numero di telefono: 02885423453
- Email: jijiyuanyuan@163.com
-
Chengdu, Sichuan, Cina
- Reclutamento
- West China Second Hospital of Sichuan University
-
Contatto:
- Hu Fan Hu, PhD
- Numero di telefono: 02885423452
- Email: 1901613702@qq.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Infants from birth through 12 months of age at their first qualifying presentation during the recruitment period at one of the three participating centers, with a segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity.
Descrizione
Inclusion Criteria
- From birth through 12 months of chronological age at enrollment.
- Clinician-confirmed segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity.
- First qualifying presentation at a participating center during the recruitment period.
- Written informed consent from a parent or legal guardian.
Exclusion Criteria
- The lesion responsible for eligibility is subsequently adjudicated to be a different vascular anomaly, such as a congenital hemangioma or vascular malformation.
- Prior enrollment in this study at any participating center.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
|---|
|
Infants With Segmental Infantile Hemangiomas
Infants with a segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity who are enrolled at one of the three participating centers. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of Evaluable Infants With PHACE Syndrome
Lasso di tempo: At enrollment through 6 months after enrollment.
|
Percentage of infants with an evaluable PHACE assessment who fulfill the revised 2016 consensus criteria for PHACE. Evaluable assessments have the prespecified core clinical, cardiac, and neurovascular evaluations documented and interpretable. Each infant is counted once. |
At enrollment through 6 months after enrollment.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Anatomic Distribution and Laterality of Segmental Hemangiomas
Lasso di tempo: At enrollment.
|
Number and percentage of infants by involved anatomic region and lesion laterality (left, right, bilateral, or midline) among infants with evaluable lesion documentation. |
At enrollment.
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Pubblicazioni e link utili
Pubblicazioni generali
- Haggstrom AN, Garzon MC, Baselga E, Chamlin SL, Frieden IJ, Holland K, Maguiness S, Mancini AJ, McCuaig C, Metry DW, Morel K, Powell J, Perkins SM, Siegel D, Drolet BA. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics. 2010 Aug;126(2):e418-26. doi: 10.1542/peds.2009-3166. Epub 2010 Jul 19.
- Garzon MC, Epstein LG, Heyer GL, Frommelt PC, Orbach DB, Baylis AL, Blei F, Burrows PE, Chamlin SL, Chun RH, Hess CP, Joachim S, Johnson K, Kim W, Liang MG, Maheshwari M, McCoy GN, Metry DW, Monrad PA, Pope E, Powell J, Shwayder TA, Siegel DH, Tollefson MM, Vadivelu S, Lew SM, Frieden IJ, Drolet BA. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. J Pediatr. 2016 Nov;178:24-33.e2. doi: 10.1016/j.jpeds.2016.07.054. Epub 2016 Sep 19. No abstract available.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 20220212
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .